(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI-driven design, high-throughput screening, bioinformatics, RNA therapies, nanotechnology, pharmacogenomics and integrated R&D platforms.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Technologies Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Drug Discovery Technologies Market to Reach $138.44 Billion by 2030 as AI and Advanced Analytics Transform Pharmaceutical Research
The global drug discovery technologies market is experiencing rapid growth as pharmaceutical and biotechnology organizations invest in advanced research platforms, automation, artificial intelligence, and data-driven development tools. The market is projected to increase from $80.76 billion in 2025 to $90.23 billion in 2026, representing a compound annual growth rate (CAGR) of 11.7%.
Historic market growth has been supported by the development of automated screening systems, expansion of genomic research, adoption of computational chemistry, increased biologics research, and the growing complexity of pharmaceutical pipelines. These factors have strengthened demand for technologies that can improve candidate identification, optimize research workflows, and reduce the time required to advance potential therapies through early-stage development.
The drug discovery technologies market is forecast to reach $138.44 billion by 2030, expanding at a CAGR of 11.3% from 2026. Key growth drivers during the forecast period include AI-driven molecular design, increased emphasis on personalized medicine, integration of advanced analytics, development of novel therapeutic modalities, and efforts to accelerate drug discovery timelines. Significant market trends include wider adoption of high-throughput screening, greater use of bioinformatics platforms, expansion of RNA-based drug discovery, growing application of nanotechnology in drug design, and integration of pharmacogenomics into research programs.
Rising healthcare expenditure is expected to remain a major driver of drug discovery technologies market growth. Higher spending associated with advanced treatments, aging populations, chronic disease prevalence, and broader access to healthcare is enabling increased investment in research platforms, analytical instruments, and digital technologies. These investments help pharmaceutical and biotechnology companies identify promising compounds, improve decision-making, and advance new therapies more efficiently.
Recent healthcare spending data supports this outlook. In May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Continued public- and private-sector healthcare investment is expected to strengthen funding for pharmaceutical research and support further adoption of drug discovery technologies.
Technology providers are responding to market demand by introducing integrated drug research and development platforms designed to improve precision, enable high-throughput analysis, enhance collaboration, and accelerate therapeutic compound discovery. In July 2023, Dotmatics Inc. launched its Small Molecule Drug Discovery Solution, featuring preconfigured workflows and advanced data management capabilities. The platform supports research from hit discovery through lead optimization and enables scientific teams to convert complex research data into actionable insights.
Strategic acquisitions are also reshaping the competitive landscape. In June 2024, Simulations Plus Inc. acquired Pro-ficiency Holdings Inc. for $100 million. The transaction is intended to expand Simulations Plus' drug discovery and development capabilities by combining simulation-based learning, intelligence, compliance, clinical trial operations, commercialization support, and data analytics. Such transactions demonstrate the growing importance of integrated digital solutions across pharmaceutical research and development.
The drug discovery technologies market covers high-throughput screening, genomics, nanotechnology, bioinformatics, combinatorial chemistry, pharmacogenomics, biochips, bioanalytical instruments, and RNA interference technologies. These solutions support the development of small-molecule and biologic drugs across cancer, immunological disorders, neurological diseases, cardiovascular conditions, and other therapeutic areas. Primary users include pharmaceutical companies, biopharmaceutical organizations, biotechnology firms, and research institutes.
North America was the largest region in the drug discovery technologies market in 2025. Regions covered by the market include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Technology: High Throughput Screening; Genomics; Nanotechnology; Bioinformatics; Combinational Chemistry; Pharmacogenomics; Biochips; Bioanalytical Instruments; Ribonucleic Acid Interface (RNAI)
2) By Drug Type: Small Molecule Drugs; Biologic Drugs
3) By Disease Application: Cancer Diseases; Immunological Diseases; Neurological Diseases; Cardiovascular Diseases; Other Disease Applications
4) By End-User: Pharmaceutical Companies; Biopharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By High Throughput Screening: Automated Screening Systems; Assay Development
2) By Genomics: DNA Sequencing; Genomic Data Analysis
3) By Nanotechnology: Nanoparticle-Based Drug Delivery; Nanomaterials For Drug Formulation
4) By Bioinformatics: Data Analysis Tools; Computational Biology Software
5) By Combinational Chemistry: Library Synthesis Techniques; Screening Methods
6) By Pharmacogenomics: Genetic Testing Platforms; Personalized Medicine Applications
7) By Biochips: Microarrays; Lab-On-A-Chip Technologies
8) By Bioanalytical Instruments: Mass Spectrometry; Chromatography Systems
9) By Ribonucleic Acid Interface (RNAI): RNA Interference Technologies; Therapeutic RNA Applications
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment